BVS (Bioventus) Total Stockholders Equity : $148.1 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Bioventus Total Stockholders Equity?

Bioventus's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $148.1 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Bioventus's Book Value per Share for the quarter that ended in Mar. 2025 was $2.24. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Bioventus's Debt-to-Equity for the quarter that ended in Mar. 2025 was 2.47.

Bioventus Total Stockholders Equity Historical Data

The historical data trend for Bioventus's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventus Total Stockholders Equity Chart

Bioventus Annual Data

Trend

Dec13

Dec14

Dec15

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

144.16

458.92

325.24

173.59

147.94

Bioventus Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															171.28	150.94	148.74	147.94	148.14

Bioventus (NAS:BVS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Bioventus's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(148.144	-	0)	/	66.231
	=	2.24

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Bioventus's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(41.699	+	324.428)	/	148.144
	=	2.47

Bioventus Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Bioventus's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioventus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioventus Inc (NAS:BVS) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703

Website

https://www.bioventus.com

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Executives

Anthony D'adamio	officer: SVP & General Counsel	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Katrina J Church	officer: SVP & Chief Compliance Officer	3290 WEST BAYSHORE ROAD, PALO ALTO CA 94303
Mark Leonard Singleton	officer: SEE REMARKS	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
John A. Bartholdson	director, 10 percent owner	C/O STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Bihl Anthony P Iii	director, officer: Interim CEO	807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Juniper Investment Company, Llc	10 percent owner	555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022-3315
Alexis P Michas	10 percent owner	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Juniper Targeted Opportunities, Lp	10 percent owner	555 MADISON AVENUE, 24TH FL, NEW YORK NY 10022
Juniper Targeted Opportunity Fund, L.p.	10 percent owner	555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022
William A Hawkins	director	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Kenneth Michael Reali	director, officer: Chief Executive Officer	5213 ATHERTON BRIDGE ROAD, RALEIGH NC 27613
John Nosenzo	officer: Chief Commercial Officer	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Alessandra Pavesio	officer: SVP & Chief Science Officer	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gregory O. Anglum	officer: SVP and CFO	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Michelle Mcmurry-heath	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703